Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

NCT06378580 is registered in ClinicalTrials.gov with Luo Cong as lead sponsor.

NCT NCT06378580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06378580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Lead sponsor
Luo Cong
Phase
Observational
Overall status
Completed
Start date
July 1, 2022
Completion date
April 1, 2024
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer